Fujian Shengdi Pharmaceutical Co., Ltd.

Quick facts

Phase 3 pipeline

• All-in-one parenteral nutrition · Nutrition support / Critical care
  All-in-one parenteral nutrition provides complete macronutrient and micronutrient support intravenously for patients unable to eat or absorb nutrients orally.
• HR19006 · Diabetes
  HR19006 is a small molecule drug that targets the SGLT2 receptor.
• HR20013 for injection；dexamethasone · Immunology / Inflammation
  Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
• HRS9531 Tablet
  HRS9531 Tablet's mechanism of action is not publicly available.

Phase 2 pipeline

• HRS-5632
• HRS-5635
• HRS-5635 Injection with Peg-IFN-α
• HRS-7249 injection set
• HRS-9057 injection set
• HRS5580
• HRS9432
• SHR-1918 injection set

Phase 1 pipeline

• [14C]HRS9531
• HR20013 for injection；dexamethason
• HRS-2162
• HRS-9057
• HRS-9531 Tablet
• HRS3797
• HRS9531 tablets

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Fujian Shengdi Pharmaceutical Co., Ltd. portfolio CI brief
• Fujian Shengdi Pharmaceutical Co., Ltd. pipeline updates RSS